Core Insights - NRx Pharmaceuticals, Inc. (NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for depression, PTSD, and suicide prevention [1] Financial Performance - The company is expected to report a Q4 2025 loss per share of approximately -$0.09 and projected revenue of around $7.53 million [2] - NRXP has a negative trailing P/E ratio of around -1.07, indicating it is not currently profitable [3] - The price-to-sales (P/S) ratio is very high at approximately 135–138, and the enterprise value to sales ratio is reported around 258–264, highlighting elevated valuation relative to current revenue [3][4] Cash Flow and Liquidity - The enterprise value to operating cash flow ratio remains negative, indicating ongoing cash burn and difficulties in generating positive cash flow from operations [4] - The company has a deeply negative earnings yield and negative shareholders' equity, leading to a negative book value per share of around -$0.93 [5] - The current ratio is 0.29, suggesting potential liquidity concerns as current assets may not sufficiently cover short-term liabilities without additional financing or revenue growth [5]